Physician profile
Andrew Sanchez
NPI 1790305746
$1,755.00
in general payments reported to CMS, 2019-2025
27 companies · $36.35 in 2025
The $36.35 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $901 · 2022: $622 · 2023: $151 · 2024: $44.89 · 2025: $36.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $307.54 | 2021-2024 | Ozempic, Rybelsus |
| Amgen INC. | $254.65 | 2021-2022 | |
| Abbvie INC. | $210.51 | 2021-2022 | |
| Astellas Pharma US INC | $130.24 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $128.69 | 2021-2023 | Farxiga |
| Lilly USA, LLC | $90.14 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Otsuka America Pharmaceutical, INC. | $69.59 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $68.27 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $50.92 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.54 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.79 | 2021-2022 | |
| Boston Scientific Corporation | $36.35 | 2025 | General - Pain Management |
| Pfizer INC. | $35.18 | 2022 | |
| Esperion Therapeutics, INC. | $33.57 | 2021 | |
| Dexcom, INC. | $31.42 | 2023 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.17 | 2022 | |
| Amarin Pharma, INC. | $23.42 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $22.15 | 2021 | |
| Inogen, INC. | $18.61 | 2022 | |
| Merck Sharp & Dohme LLC | $17.67 | 2022 | |
| Eisai INC. | $17.32 | 2021 | |
| Medtronic, INC. | $16.02 | 2021 | |
| Glaxosmithkline, LLC. | $15.78 | 2021 | |
| Roche Diabetes Care, INC. | $15.60 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.41 | 2022 | |
| Exact Sciences Corporation | $14.08 | 2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.